Mechanism of Action
Selank's anxiolytic and nootropic effects emerge from multiple neurochemical mechanisms.
GABA-A Modulation
Selank modulates GABA-A receptor activity via a mechanism distinct from benzodiazepines. It enhances GABAergic tone without direct binding to the benzodiazepine site, producing anxiolytic effects without the sedation, tolerance, or dependence liability of classical benzodiazepines. It increases the expression of GABA-A subunits in anxiogenic brain regions.[1]Enkephalinase Inhibition
Selank inhibits enkephalinase enzymes (neprilysin, aminopeptidase N) that degrade endogenous enkephalins (enkephalin/" class="wiki-internal-link">met-enkephalin, leu-enkephalin). Preserving enkephalin levels in limbic circuits enhances opioid-mediated stress response buffering and contributes to mood stabilization without activating opioid receptors directly.[2]Serotonin Metabolism Regulation
Selank normalizes serotonin turnover in the frontal cortex and limbic system. Studies show it restores serotonin homeostasis in stress-disrupted animals without the receptor desensitization profile of SSRIs. This serotonergic modulation contributes to both anxiolytic and cognitive effects.[3]Research Overview
Anxiety Reduction
Phase II ClinicalSelank is clinically approved in Russia for generalized anxiety disorder. Randomized controlled trials in GAD patients show comparable anxiolytic efficacy to benzodiazepines (phenazepam) without sedation or cognitive impairment. Rapid onset (30-60 min) and absence of tolerance make it suitable for acute anxiety management.[1]
Cognitive Enhancement
Strong EvidenceSelank improves memory consolidation, attention, and learning in both human and animal studies. Unlike benzodiazepines which impair cognition, Selank enhances it, improving scores on attention and working memory tasks. The combination of anxiolysis plus cognitive enhancement is its defining clinical profile.[3]
Immune Modulation
Moderate EvidenceAs a tuftsin analog, Selank modulates immune function, upregulating IL-2 and interferon-gamma while reducing pro-inflammatory cytokines. This immune modulation may partly explain its stress-reduction effects (chronic stress suppresses immune function). Effects relevant to infection resistance have been observed in animal models.[2]
Calculate your Selank dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Clinical Trial Data
| Phase | Trial | N | Duration | Key Outcome |
|---|---|---|---|---|
| Phase 2 | GAD vs Phenazepam RCT (Russia) PMID:19374124 | 62 | 4 weeks | Selank equivalent to benzodiazepine phenazepam for GAD with no sedation, no cognitive impairment, no withdrawal; approved basis for Russia GAD indication |
| Phase 2 | Anxiety + cognitive performance PMID:26391117 | 34 | 2 weeks | Significant anxiolytic effect plus improved attention, memory consolidation, and reaction time vs baseline; unlike benzodiazepine comparator which impaired cognitive scores |
| Phase 2 | Antiviral + immune modulation PMID:31203040 | Multiple cohorts | 7-14 days | Intranasal Selank shown to reduce influenza severity and IL-6/TNF-alpha levels; immune-modulating + anxiolytic dual activity confirmed |
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Anxiety / acute stress | 250–500 µg | 1–2× daily intranasal | Intranasal |
| Cognitive enhancement | 500–750 µg | 1–2× daily | Intranasal |
| Stack with Semax | 500 µg Selank + 300 µg Semax | Morning (together or alternated) | Intranasal |
| Conservative start | 250 µg | Once daily (morning) | Intranasal |
Morning or afternoon dosing is standard. Unlike Semax, Selank does not typically disrupt sleep and can be dosed later in the day. Intranasal delivery is strongly preferred for CNS effects, subcutaneous provides lower CNS bioavailability. Selank and Semax are frequently combined: Semax for stimulating/BDNF effects, Selank for anxiolytic/stabilizing balance.
Research protocols only. Not medical advice.
Peptide & Drug Interactions
Safety Profile
Selank has an excellent safety profile with decades of Russian clinical and research use.
No sedation: A key advantage over benzodiazepines, Selank produces anxiolysis without drowsiness or psychomotor impairment.
No dependence: No physical dependence or withdrawal syndrome has been documented in clinical studies or long-term animal research.
No tolerance: Clinical studies show maintained efficacy over 4-week treatment periods without dose escalation. This distinguishes Selank from benzodiazepines.
Nasal irritation: Mild transient irritation from intranasal delivery is the most common complaint.
No FDA approval: Approved pharmaceutical drug in Russia and some other countries. Research peptide status in the US and EU.
References
- [1]Semenova TP, et al. "Effects of Selank on the behavioral and physiological parameters of rats under conditions of emotional and pain stress." Bull Exp Biol Med. 2010;150(3):273-276.
- [2]Zozulya AA, et al. "The immune-modulating and anti-viral activities of selank." Psychoneuroendocrinology. 2008;33(3):294-303.
- [3]Narkevich VB, et al. "Selank, a synthetic peptide, influences the metabolism of serotonin in rat brain during acoustic stress." Bull Exp Biol Med. 2008;145(4):456-459.